<DOC>
	<DOCNO>NCT00776321</DOCNO>
	<brief_summary>Eprotirome ( KB2115 ) liver selective thyroid hormone induce hyperthyroidism liver , euthyroid state preserve extrahepatic tissue . Eprotirome clinical 2-weeks study demonstrate pronounced reduction independent risk factor development atherosclerotic cardiovascular disease . The purpose study assess efficacy safety KB2115 monotherapy follow 12 week exposure compare placebo . The aim study ass efficacy ( LDL-cholesterol lower effect ) safety KB2115 .</brief_summary>
	<brief_title>Eprotirome Treatment Dyslipidemia , Efficacy Safety 12-Week , Phase ii Study Assess Safety Efficacy KB2115 Patients With Primary Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>clinical diagnosis hypercholesterolemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>hypercholesterolemia</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>thyroid</keyword>
	<keyword>safety</keyword>
</DOC>